20211124

Media Featured Story on Heartseed was listed on Science Japan by Japan Science and Technology Agency (JST).
"Developing a next-generation therapy for severe heart failure using iPS cells"

2021810

PR Heartseed named "Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award" at Academic Startups 2021

202172

Other LAPiS Study, a Phase I/II Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With HF is posted on ClinicalTrials.gov

2021622

Congress Kikuo Yasui, COO speaks at the International Society for Stem Cell Research (ISSCR) 2021, "Driving Change in Regenerative Medicine Through Global Partnerships: Organized by Novo Nordisk Stem Cell R&D"

2021615

Congress Keiichi Fukuda, CEO gave a presentation titled "Clinical Application of Human iPS Cell-Derived Ventricular Cardiomyocytes for Heart Failure Treatment" at Deep Tech in Asia: Stem Cell Innovations by SGInnovate.

2021611

PR Heartseed raises $37 million in Series C Funding

2021611

Other Tatsuyoshi Hirano was appointed as Chief Administrative Officer

202161

PR Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure

2021510

Media An interview with Kikuo Yasui, COO, was published in the Japan Times.

2021421

Media Heartseed was featured as a cover story in Startup City Magazine's "Top 10 Startups in Japan"